Prostate cancer has a long disease history and a wide variety and uncertainty in individual
patients' clinical progress. In recent years, we have seen a revolutionary advance in both …

In recent years, advancements in single-cell and spatial transcriptomics, which are highly
regarded developments in the current era, particularly the emerging integration of single-cell …

Cell plasticity has been found to play a critical role in tumor progression and therapy
resistance. However, our understanding of the characteristics and markers of plastic cellular …

Prostate cancer (PCa) is a malignant disorder of prostate gland being asymptomatic in early
stages and high metastatic potential in advanced stages. The chemotherapy and surgical …

Neuroendocrine prostate carcinoma (NEPC) accounts for less than 1% of prostate
neoplasms and has extremely poorer prognosis than the typical androgen receptor pathway …

Neuroendocrine prostate cancer (NEPC) typically implies severe lethality and limited
treatment options. The precise identification of NEPC cells holds paramount significance for …

Background The prognostic and therapeutic implications of endothelial cells (ECs)
heterogeneity in prostate cancer (PCa) are poorly understood. Methods We investigated …

Abstract Treatment-induced neuroendocrine prostate cancer (t-NEPC) often arises from
adenocarcinoma via lineage plasticity in response to androgen receptor signaling inhibitors …

Background Cancer cell plasticity is the ability of neoplastic cells to alter their identity and
acquire new biological properties under microenvironmental pressures. In prostate cancer …

Prostate cancer (PCa) is a prevalent malignancy among men, with a majority of patients
presenting with distant metastases at the time of initial diagnosis. These patients are at a …